NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Well folks, as shocking as it may be, I have LC to thank for linking me to the JCI publication… Now, I can appreciate more fully how the combo implications are potentially vast and game-changing … I am not an oncologist, but I find this technology fascinating as a platform…

Soon after LC posted the link to JCI, the Merck PR was published about the ADC deal, and then I went back to reread the article again and I watched some videos of Dr. Liau’s discussions on the topic of combo therapy..

✅ DCVax-L is efficacious (see JAMA Oncology).

✅ DCVax-L + PD1 is perhaps far more efficacious than DCVax-L as a monotherapy (see interim survival data).

⭐️ DCVax-L technology + PD1 technology + ADC technology could be yet another breakthrough … The P3 that was published in JAMA Oncology looks like only the tip of an enormous iceberg!

Perhaps without realizing it, I think LC may have actually dropped the mic after announcing the JCI publication!

Combo is King!

https://www.cell.com/trends/cancer/fulltext/S2405-8033(23)00005-5

https://thehealthcaretechnologyreport.com/merck-and-daiichi-sankyo-enter-landmark-5-5-billion-partnership/

https://www.jci.org/articles/view/169314



The Nobel Prize was a harbinger of the novel DCVax-L cell-based platform technology!

https://www.livescience.com/16354-nobel-prize-medicine-2011-immune-research.html




Dr. Steinman’s work lives on at UCLA!

https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials